Novartis AG (SWX:NOVN)
91.07
-0.04 (-0.04%)
May 9, 2025, 2:25 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.62B USD in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
3.79
Revenue / Employee
$701.37K
Employees
75,883
Market Cap
178.51B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Lonza Group AG | 6.57B |
Alcon | 8.98B |
Galderma Group AG | 4.02B |
Straumann Holding AG | 2.50B |
Sandoz Group AG | 9.41B |
Sonova Holding AG | 3.71B |
Ypsomed Holding AG | 617.07M |
Novartis AG News
- 2 days ago - China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief - Financial Times
- 2 days ago - PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Benzinga
- 3 days ago - BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion - Benzinga
- 4 days ago - BioNTech says Novartis executive Zapata-Gomez to become CFO - Reuters
- 5 days ago - Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
- 5 days ago - Key deals this week: Gold Fields, Palo Alto, Novartis, LendingClub and more - Seeking Alpha
- 7 days ago - Final Trade: NVS, XLU and SMMT - CNBC
- 7 days ago - Regulus CVR may be worth $3-$4 a share in Novartis deal - analyst - Seeking Alpha